Literature DB >> 9545527

Stringent structural requirements for anti-Ras activity of S-prenyl analogues.

Z Aharonson1, M Gana-Weisz, T Varsano, R Haklai, D Marciano, Y Kloog.   

Abstract

The carboxy terminal S-farnesylcysteine of Ras oncoproteins is required for their membrane anchorage and transforming activities. We showed previously that S-farnesylthiosalicylic acid (FTS) affects the membrane anchorage of activated H-Ras in EJ cells and inhibits their growth. We report here on structural elements in S-prenyl derivatives that specifically inhibit the growth of EJ cells, but not of untransformed Rat-1 cells. Inhibition of the Ras-dependent extracellular signal-regulated protein kinase (ERK), of DNA synthesis and of EJ cell growth were apparent after treatment with FTS or its 5-fluoro, 5-chloro and 4-fluoro derivatives or with the C20 S-geranylgeranyl derivative of thiosalicylic acid. The 4-Cl-FTS analogue was a weak inhibitor of EJ cell growth. The 3-Cl-FTS analogue and the FTS carboxyl methyl ester were inactive, as were the C10 S-geranyl derivative of thiosalicylic acid, farnesoic acid, N-acetyl-S-farnesyl-L-cysteine and S-farne-sylthiopropionic acid. The structural requirements for anti-Ras activity of S-prenyl analogues thus appear to be rather stringent. With regard to chain length, the C15 farnesyl group linked to a rigid backbone seems to be necessary and sufficient. A free carboxyl group in an appropriately rigid orientation, as in thiosalicylic acid, is also required. Halogenic substitutents on the benzene ring of the thiosalicylic acid are tolerated only at position 5 or 4. This information may facilitate the design of potent Ras antagonists and deepen our understanding of the mode of association of Ras with the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545527     DOI: 10.1016/s0925-4439(97)00077-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Novel Ras antagonist blocks human melanoma growth.

Authors:  B Jansen; H Schlagbauer-Wadl; H Kahr; E Heere-Ress; B X Mayer; H Eichler; H Pehamberger; M Gana-Weisz; E Ben-David; Y Kloog; K Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).

Authors:  A Katzav; Y Kloog; A D Korczyn; H Niv; D M Karussis; N Wang; R Rabinowitz; M Blank; Y Shoenfeld; J Chapman
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 4.  Targeting the RAS pathway in melanoma.

Authors:  Zhenyu Ji; Keith T Flaherty; Hensin Tsao
Journal:  Trends Mol Med       Date:  2011-09-30       Impact factor: 11.951

5.  Repositioning Salirasib as a new antimalarial agent.

Authors:  Exequiel O J Porta; Ignasi Bofill Verdaguer; Consuelo Perez; Claudia Banchio; Mauro Ferreira de Azevedo; Alejandro M Katzin; Guillermo R Labadie
Journal:  Medchemcomm       Date:  2019-06-21       Impact factor: 3.597

Review 6.  Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation.

Authors:  Hiu Yeung Lau; Mei Wang
Journal:  Small GTPases       Date:  2018-01-25

7.  An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease.

Authors:  Avijit Ray; Sreemanti Basu; Nichole M Miller; Andrew M Chan; Bonnie N Dittel
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

8.  Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Ming Zhao; Ping He; Linping Xu; Manuel Hidalgo; Dan Laheru; Michelle A Rudek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-05-22       Impact factor: 3.205

9.  Ras inhibition induces insulin sensitivity and glucose uptake.

Authors:  Adi Mor; Elizabeta Aizman; Jacob George; Yoel Kloog
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

10.  Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death.

Authors:  Sari Schokoroy; Dolly Juster; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.